SCHEMBL4516571

SCHEMBL4516571

CN(C)C(=O)N(CCCc1ccc(C#N)cc1)CCN1CC2CN(C(=O)OC(C)(C)C)CC(C1)O2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.40
HTR1A P08908 2/20 0.37
DRD4 P21917 2/20 0.37
HTR2A P28223 2/20 0.37
HRH1 P35367 2/20 0.37
OPRM1 P35372 2/20 0.37
NAMPT P43490 1/20 0.35
KCNH2 Q12809 2/20 0.35
EGLN2 Q96KS0 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
AR P10275 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
CACNA1F O60840 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD5 P21918 1/20 0.34
HRH2 P25021 1/20 0.34
ADRA1D P25100 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524719 0.88 GPR119 (0.42) GPR119HRH1KCNH2EGLN2HRH2
SCHEMBL4508018 0.88 GPR119 (0.40) GPR119HTR1ADRD4HTR2AHRH1
SCHEMBL2967666 0.87 GPR119 (0.44) GPR119HTR1ADRD4HTR2AHRH1
SCHEMBL4516189 0.84 HRH1 (0.36) HTR1ADRD4HTR2AHRH1OPRM1
SCHEMBL3120415 0.80 GPR119 (0.40) GPR119NAMPTKCNH2EGLN2FNTA
SCHEMBL4516175 0.80 KCNH2 (0.42) HRH1KCNH2DRD2HRH2DRD3
SCHEMBL3121813 0.80 GPR119 (0.48) GPR119NAMPTEGLN2ARALDH1A1
SCHEMBL4508020 0.80 KCNH2 (0.44) GPR119HTR1ADRD4HTR2AHRH1
Hydrochloric Acid SCHEMBL4667417 0.79 GPR119 (0.47) GPR119NAMPTEGLN2ARALDH1A1
SCHEMBL4512493 0.79 GPR119 (0.42) GPR119HRH1KCNH2EGLN2HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099162-A2 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20080319198-A2 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080249086-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2008-10-09 US disclosed
US-20080207899-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080146812-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2008-06-19 US disclosed
US-7354917-B2 Oxabispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2008-04-08 US disclosed
US-20070259864-A1 Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2007-11-08 US disclosed
EP-1765831-A1 NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2005123747-A1 NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099162-A2 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885
US-20080207899-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885
US-20070259864-A1 Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885
US-20080146812-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885
US-20080319198-A2 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885
US-20080249086-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E GPR119 2153/4885HTR1A 2932/4885DRD4 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.